Insulin Therapy Articles & Analysis
18 news found
Although research categorizes LADA as autoimmune diabetes, the disease is still in most cases treated according to the guidelines for type 2 diabetes. LADA patients are usually not insulin dependent at diagnosis, but for most patients, insulin therapy is required within a few years of diagnosis. About Diamyd Medical Diamyd Medical develops ...
Although research categorizes LADA as autoimmune diabetes, the disease is still in most cases treated according to the guidelines for type 2 diabetes. LADA patients are usually not insulin dependent at diagnosis, but for most patients, insulin therapy is required within a few years of diagnosis. About Diamyd Medical Diamyd Medical develops ...
Although research categorizes LADA as autoimmune diabetes, the disease is still in most cases treated according to the guidelines for type 2 diabetes. LADA patients are usually not insulin dependent at diagnosis, but for most patients, insulin therapy is required within a few years of diagnosis. About Diamyd Medical Diamyd Medical develops ...
Analysis revealed that the EndoBarrier System met overall glycemic control efficacy and SAE related device removal safety endpoints, while also providing clinically significant weight loss, and comorbidity improvement. “Insulin therapy is associated with poor long-term outcomes in patients with type 2 diabetes mellitus and obesity, and bariatric surgery is ...
The patients included in the trial are between 30 and 70 years old, have been diagnosed with LADA within the last 18 months and are not yet on insulin therapy. The Sponsor of the trial is the Norwegian University of Science and Technology with Ingrid K Hals as Sponsor's representative. ...
Revita has already received a CE Mark in Europe to improve glycemic control in patients with inadequately controlled T2D on antidiabetic agents and/or long-acting insulin therapy. German hospitals may now negotiate full reimbursement from the national health insurance system for its use in their patients in clinical studies and/or real-world evidence generation ...
Per protocol, insulin therapy will be re-introduced, if and when necessary, to help patients achieve good glycemic control. ...
The trial is now enrolling patients with type 2 diabetes who are currently on insulin therapy at the following locations: Saint Joseph’s Medical Center in Paterson, N.J.; The Academic Medical Center in Amsterdam; Tulane Medical Center in New Orleans; Baylor St. ...
(OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, today announced the expansion of its executive team with the appointment of Lynn O'Connor Vos as its new Chief Executive Officer. ...
Toronto, Canada, July 27, 2021 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01. ...
(“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has successfully completed a Phase 1 study evaluating single and multiple ascending doses of ZT-01. ...
The trial, called REVITA-T2Di, will evaluate the ability of a single Revita DMR treatment to allow patients currently on insulin therapy but with inadequate glycemic control to achieve durable insulin-free glycemic control. ...
In the INSPIRE study, 16 insulin-treated patients with type 2 diabetes (T2D) underwent a single treatment with Revita DMR after which they ceased insulin therapy and began treatment with GLP-1RA and lifestyle counseling. At six months after Revita DMR treatment, 11 out of 16 patients (69%) remained off insulin ...
Toronto, Canada, September 29, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. “Initiation of our Phase 1 study of ZT-01, which has been our goal since ...
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. “Initiation of our Phase 1 study of ZT-01, which has been our goal since establishing the Company in 2014, is a ...
Revita T2Di pivotal study to evaluate the ability of Revita DMR, the first non-drug, non-surgical, disease-modifying therapy, to eliminate need for insulin injections in T2D; enrollment expected to begin in late 2020 LEXINGTON, Mass., June 3, 2020 — Fractyl Laboratories Inc. ...
The proceeds from the financing will fund Phase 1 and Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D and other types of insulin-dependent diabetes. ...
The proceeds from the financing will fund Phase 1 and Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D and other types of insulin-dependent diabetes. ...